Boryung Pharmaceutical Co., Ltd

Quick facts

Marketed products

• Aspirin enteric coated pellests 100mg
• Dapagliflozin/Pioglitazone · Diabetes
  This combination drug reduces blood glucose by inhibiting SGLT2 to increase urinary glucose excretion and activating PPAR-γ to improve insulin sensitivity.
• Dapagliflozin/Sitagliptin · Diabetes
  This combination drug lowers blood glucose by inhibiting SGLT2 to increase urinary glucose excretion and inhibiting DPP-4 to increase incretin levels.
• Treatment R · Cardiovascular
  Treatment R is a calcium channel blocker that works by relaxing blood vessels and reducing blood pressure.
• Treatment T · Cardiovascular
  Treatment T is a calcium channel blocker that works by inhibiting the influx of calcium ions into cardiac and vascular smooth muscle cells.

Phase 3 pipeline

• BR1018A · Oncology
  BR1018A is an investigational therapeutic targeting immune checkpoint pathways to enhance anti-tumor immunity.
• BR1018A-1 · Cardiovascular
  BR1018A-1 is a small molecule drug that targets the renin-angiotensin system.
• BR1018B
  BR1018B is a therapeutic agent in phase 3 development by Boryung Pharmaceutical, but its specific mechanism of action is not publicly disclosed.
• BR1018B-1 · Cardiovascular
  BR1018B-1 is a small molecule that targets the renin-angiotensin system.
• BR1018C
  BR1018C is a therapeutic agent in phase 3 development by Boryung Pharmaceutical, but its specific mechanism of action is not publicly disclosed.
• BR1018C-1 · Cardiovascular
  BR1018C-1 is a small molecule that targets the renin-angiotensin system.
• BR1019A
  BR1019A is an investigational therapeutic in phase 3 development by Boryung Pharmaceutical, but its specific mechanism of action is not publicly disclosed.
• BR1019A-1 · Cardiovascular
  BR1019A-1 is a small molecule that targets the renin-angiotensin system.
• BR1019B
  BR1019B is an investigational therapeutic in phase 3 development by Boryung Pharmaceutical, but its specific mechanism of action is not publicly disclosed.
• BR1019B-1 · Cardiovascular
  BR1019B-1 is a small molecule drug that targets the renin-angiotensin system.
• BR1019C
  BR1019C is an investigational therapeutic agent in phase 3 development by Boryung Pharmaceutical, but its specific mechanism of action is not publicly disclosed.
• BR1019C-1 · Cardiovascular
  BR1019C-1 is a small molecule drug that targets the renin-angiotensin system.
• DTaP vaccine and IPV vaccine · Immunology
  This combination vaccine stimulates the immune system to produce antibodies and cellular immunity against diphtheria, tetanus, pertussis, and poliovirus.
• Fimasartan/Amlodipine combination · Cardiovascular
  Fimasartan blocks angiotensin II receptors to lower blood pressure, while amlodipine blocks calcium channels to relax blood vessels, providing dual antihypertensive action.
• Fimasartan/Amlodipine, Rosuvastatin · Cardiovascular
  This combination drug lowers blood pressure through angiotensin II receptor blockade and calcium channel inhibition, while simultaneously reducing cholesterol via HMG-CoA reductase inhibition.
• Fimasartan and Amlodipine · Cardiovascular
  Fimasartan blocks angiotensin II receptors to lower blood pressure, while amlodipine relaxes blood vessels by blocking calcium channels, providing dual antihypertensive action.
• Fimasartan and Rosuvastatin · Cardiovascular
  Fimasartan blocks angiotensin II receptors to lower blood pressure, while rosuvastatin inhibits HMG-CoA reductase to reduce cholesterol synthesis.
• Fimasartan/HCTZ combination · Cardiovascular
  Fimasartan blocks angiotensin II type 1 receptors to lower blood pressure, while hydrochlorothiazide acts as a thiazide diuretic to reduce fluid volume and further decrease blood pressure.
• Fimasartan + Indapamide · Cardiovascular
  Fimasartan blocks angiotensin II receptors to lower blood pressure, while indapamide acts as a thiazide-like diuretic to reduce fluid volume and further decrease blood pressure.
• Fimasartan or Fimasartan/Hydrochlorothiazide · Cardiovascular
  Fimasartan is an angiotensin II receptor blocker (ARB) that selectively antagonizes the AT1 receptor to reduce vasoconstriction and lower blood pressure.
• Fimasartan, Rosuvastatin · Cardiovascular
  Fimasartan is an angiotensin II receptor blocker that reduces blood pressure, while rosuvastatin is a statin that lowers cholesterol; together they address hypertension and dyslipidemia.
• Havrix Inj · Immunology / Infectious Disease
  Havrix is an inactivated hepatitis A vaccine that stimulates the immune system to produce antibodies against hepatitis A virus.
• JE vaccine · Infectious Disease / Immunology
  JE vaccine stimulates the immune system to produce antibodies and cellular immunity against Japanese encephalitis virus.
• Losartan (Control) · Cardiovascular
  Losartan blocks angiotensin II type 1 (AT1) receptors, preventing vasoconstriction and aldosterone release to lower blood pressure.
• Perindopril or Perindopril/Indapamide · Cardiovascular
  Perindopril is an angiotensin-converting enzyme (ACE) inhibitor that blocks the conversion of angiotensin I to angiotensin II, thereby reducing blood pressure and heart workload.

Phase 2 pipeline

• BR101801
• BR1400-1 · Cardiovascular
  BR1400-1 is a small molecule that targets the renin-angiotensin system.
• BR1400-2
• BR1400-3 · Cardiovascular
  BR1400-3 is a small molecule that targets the renin-angiotensin system.
• BR1400-4
• BR1400-5
• BR1400-A · Cardiovascular
  BR1400-A is a small molecule that targets the renin-angiotensin system.
• BR1400-B
  BR1400-B is an investigational therapeutic in phase 2 development by Boryung Pharmaceutical with an undisclosed or proprietary mechanism of action.
• BR1400-C · Cardiovascular
  BR1400-C is a small molecule that targets the renin-angiotensin system.
• BR5402A · Diabetes
  BR5402A is a small molecule that targets the SGLT2 receptor.
• BR5402A-1 · Cardiovascular
  BR5402A-1 is a small molecule that targets the HMG-CoA reductase enzyme.
• BR5402B
• BR5402B-1 · Diabetes
  BR5402B-1 is a small molecule that targets the SGLT2 receptor.
• BR5402C · Oncology
  BR5402C is a small molecule that targets the HIF-1α pathway.
• BR5402C-1
• BR5402D
• BR5402D-1

Phase 1 pipeline

• BR-A-657
• BR1015
• BR1015-1
• BR1015-2
• BR1015-3
• BR1015-A
• BR1016A
• BR1016B
• BR1016C
• BR1016D
• BR1017-1
• BR1017-1A
• BR1017-1B
• BR1017-2
• BR1018
• BR1018-1
• BR1018-2
• BR1019
• BR1019-1
• BR1019-2
• BR1019-3
• BR2021
• BR2021-1
• BR3005
• BR3005-1
• BR3005-2
• BR3006
• BR3006-1
• BR3006-2
• BR3006-3
• BR3006A
• BR3006B
• BR3006C
• BR3409
• BR3409-1
• BR3409-2
• BR4002
• BR4002-1
• BR6001-1
• BR6001-2

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Boryung Pharmaceutical Co., Ltd portfolio CI brief
• Boryung Pharmaceutical Co., Ltd pipeline updates RSS